Psoriasis duration may accelerate development of vascular disease, MACE
Duration of psoriasis poses harmful effects on vascular inflammation and major adverse cardiovascular (CV) event (MACE), a recent study has found. This suggests that cumulative duration of exposure to low-grade chronic inflammation may fast-track vascular disease development and MACEs.
To understand the effect of psoriasis duration on vascular disease and CV events, researchers utilized two resources, namely a human imaging study and a population-based study of CV disease (CVD) events.
Patients with psoriasis (n=190) went through fludeoxyglucose F 18 positron emission tomography/computed tomography (duration effect reported as a β-coefficient). Nationwide registries were then used to examine MACE risk (adjusted hazard ratios [HRs] in patients with psoriasis: n=87,161 vs general population: n=4,234,793).
Overall, patients in the human imaging study were young, of low CV risk by traditional risk scores and had a high prevalence of cardiometabolic diseases. A significant association existed between vascular inflammation by fludeoxyglucose F 18 positron emission tomography/computed tomography and disease duration (β=0.171; p=0.002).
In the population-based study, there was a strong association between psoriasis duration and MACE risk (1.0 percent per additional year of psoriasis duration; HR, 1.010; 95 percent CI, 1.007 to 1.013).
In light of these findings, “[p]roviders should consider inquiring about duration of disease to counsel for heightened CVD risk in psoriasis,” according to researchers, adding that the use of observational data was one limitation of their study.
In another study, Harrington and colleagues stated that “[i]nflammation is known to play a significant role in the process of atherogenesis and cardiovascular disease. Indeed, patients with chronic inflammatory diseases are at increased risk for cardiovascular events.” [Am J Physiol Heart Circ Physiol 2017;312:H867-H873]